Q2 2022 13F Holders as of 6/30/2022
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
38.2M
-
Number of holders
-
32
-
Total 13F shares, excl. options
-
24.8M
-
Shares change
-
-1.1M
-
Total reported value, excl. options
-
$302M
-
Value change
-
-$13M
-
Number of buys
-
10
-
Number of sells
-
-29
-
Price
-
$12.18
Significant Holders of Entrada Therapeutics, Inc. - Common Stock, par value $0.0001 per share (TRDA) as of Q2 2022
50 filings reported holding TRDA - Entrada Therapeutics, Inc. - Common Stock, par value $0.0001 per share as of Q2 2022.
Entrada Therapeutics, Inc. - Common Stock, par value $0.0001 per share (TRDA) has 32 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 24.8M shares
of 38.2M outstanding shares and own 64.84% of the company stock.
Largest 10 shareholders include BAKER BROS. ADVISORS LP (4.87M shares), MPM ASSET MANAGEMENT LLC (4.43M shares), 5AM Venture Management, LLC (4.41M shares), PRICE T ROWE ASSOCIATES INC /MD/ (2.44M shares), Redmile Group, LLC (1.95M shares), WELLINGTON MANAGEMENT GROUP LLP (1.54M shares), FMR LLC (945K shares), VANGUARD GROUP INC (762K shares), TCG Crossover Management, LLC (664K shares), and StepStone Group LP (635K shares).
This table shows the top 32 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.